Claire Thiriez

Dr. Claire Thiriez


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in The Lancet
Verified
Journal Article
Closed access
SPStéphane Palfi
Stéphane Palfi
JGJean Marc Gurruchaga
Jean Marc Gurruchaga
GRG Scott Ralph
G Scott Ralph
HLHelene Lepetit
Helene Lepetit
SLSonia Lavisse
Sonia Lavisse
KMKyriacos A Mitrophanous
Kyriacos A Mitrophanous

28 September 2017 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GVG. Villafane
G. Villafane
CTClaire Thiriez
Claire Thiriez
EAEtienne Audureau
Etienne Audureau
CSC. Straczek
C. Straczek
PKP. Kerschen
P. Kerschen
GFG. Fénelon
G. Fénelon

29 May 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
SLSonia Lavisse
Sonia Lavisse
DGDaniel García-Lorenzo
Daniel García-Lorenzo
MPMarie-Anne Peyronneau
Marie-Anne Peyronneau
BBBenedetta Bodini
Benedetta Bodini
CTClaire Thiriez
Claire Thiriez
MBMichel Bottlaender
Michel Bottlaender
Translocator protein (TSPO) is expressed at a low level in healthy brain and is upregulated during inflammatory processes that may occur in neurodegenerative diseases. Thus, TSPO may be a suitable in vivo indicator of neurodegeneration. Here, we quantified the 18F-DPA-714 radioligand in healthy TSPO-genotyped volunteers and developed a method to eliminate the need for invasive arterial blood sampling. Methods: Ten controls (7 high-affinity binders [HABs] and 3 mixed-affinity binders [MABs]) underwent 18F-DPA-714 PET with arterial and venous sampling. 18F-DPA-714 binding was quantified with a metabolite-corrected arterial plasma input function, using the 1- and 2-tissue-compartment models (TCMs) as well as the Logan analysis to estimate total volume distribution (VT) in the regions of interest. Alternative quantification methods were tested, including tissue-to-plasma ratio or population-based input function approaches normalized by late time points of arterial or venous samples. Results: The distribution pattern of 18F-DPA-714 was consistent with the known distribution of TSPO in humans, with the thalamus displaying the highest binding and the cerebellum the lowest. The 2-TCM best described the regional kinetics of 18F-DPA-714 in the brain, with good identifiability (percentage coefficient of variation < 5%). For each region of interest, VT was 47.6% ± 6.3% higher in HABs than in MABs, and estimates from the 2-TCM and the Logan analyses were highly correlated. Equilibrium was reached at 60 min after injection. VT calculated with alternative methods using arterial samples was strongly and significantly correlated with that calculated by the 2-TCM. Replacement of arterial with venous sampling in these methods led to a significant but lower correlation. Conclusion: Genotyping of subjects is a prerequisite for a reliable quantification of 18F-DPA-714 PET images. The 2-TCM and the Logan analyses are accurate methods to estimate 18F-DPA-714 VT in the human brain of both HAB and MAB individuals. Population-based input function and tissue-to-plasma ratio with a single arterial sample are promising alternatives to classic arterial plasma input function. Substitution with venous samples is promising but still requires methodologic improvements.

1 July 2014 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
CTClaire Thiriez
Claire Thiriez
JGJean-Marc Gurruchaga
Jean-Marc Gurruchaga
CGColette Goujon
Colette Goujon
GFGilles Fénelon
Gilles Fénelon
SPStéphane Palfi
Stéphane Palfi

1 July 2011 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
CTClaire Thiriez
Claire Thiriez
GVGabriel Villafane
Gabriel Villafane
FGFrédérique Grapin
Frédérique Grapin
GFGilles Fenelon
Gilles Fenelon
PRPhilippe Remy
Philippe Remy
PCPierre Cesaro
Pierre Cesaro
The risk of Parkinson's disease is reduced by cigarette smoking, which raises some unanswered questions. Nicotine, a major component of tobacco smoke, could exert either nonreceptor-mediated biological effects or, more importantly, act on the different subtypes of nicotinic brain receptors, in particular those associated with the nigrostriatal dopaminergic pathway. There is now robust experimental evidence for a neuroprotective effect of nicotine upon dopaminergic neurons. By contrast, in animal models of Parkinson's disease, nicotine alone has slight or no motor effects. However, nicotine may modulate dopamine transmission and has clear motor effects when associated with L-DOPA, reducing L-DOPA-induced dyskinesias. Clinical trials have yielded inconclusive results thus far and are hampered by different designs and small cohorts. Ongoing studies address either symptomatic motor or nonmotor symptoms, or neuroprotection. There is still no agreement on the daily dosage of nicotine or the method of administration. Together, these data suggest that nicotine or nicotinic receptor drugs have therapeutic potential for Parkinson's disease, although the specific treatment regimens remain to be determined.

18 February 2015 in Stereotactic and Functional Neurosurgery
Verified
Journal Article
Closed access
PDF file
SSSuhan Senova
Suhan Senova
DQDamien Querlioz
Damien Querlioz
CTClaire Thiriez
Claire Thiriez
PJPierre Jedynak
Pierre Jedynak
BJBéchir Jarraya
Béchir Jarraya
SPStéphane Palfi
Stéphane Palfi
Background/Aims: Evaluation of tremor constitutes a crucial step from the diagnosis to the initial treatment and follow-up of patients with essential tremor. The severity of tremor can be evaluated using clinical rating scales, accelerometry, or electrophysiology. Clinical scores are subjectively given, may be affected by intra- and interevaluator variations due to different experience, delays between consultations, and subtle changes in tremor severity. Existing medical devices are not routinely used: they are expensive, time-consuming, not easily accessible. We aimed at showing that a smartphone application using the accelerometers embedded in smartphones is effective for quantifying the tremor of patients presenting with essential tremor. Methods: We developed a free iPhone/iPod application, Itremor, and evaluated different parameters on 8 patients receiving deep brain stimulation of the ventral intermediate nucleus of the thalamus: average and maximum accelerations, time above 1 g of acceleration, peak frequency, typical magnitude of tremor, for postural and action tremors, on and off stimulation. Results: We demonstrated good correlations between the parameters measured with Itremor and clinical score in all conditions. Itremor evaluation enabled higher discriminatory power and degree of reproducibility than clinical scores. Conclusion: Itremor can be used for routine objective evaluation of essential tremor, and may facilitate adjustment of the treatment.